Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Traws Pharma, Inc.TRAW · Entity 8032 | Chief Science Officer Virology | July 09, 2026 | July 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Traws Pharma, Inc.
Report date July 09, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09 | Direct | 97,000 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 97,000 · Balance 97,000 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 16, 2026 16:39 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 97,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0002018150-26-000003 · form4-07162026_040743.xml · derivative · entry 1 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 23:18 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 118,367 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0002018150-26-000002 · form4-03102026_110321.xml · derivative · entry 1 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,367 Underlying: Common Stock · 118,367 shares Expires 2036-03-08 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:16 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 73,886 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0002018150-25-000004 · form4-12162025_111219.xml · derivative · entry 2 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,886 Underlying: Common Stock · 73,886 shares Expires 2035-12-12 F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:16 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 18,471 | $0.00 | $0.00 |
DisclosureSEC source: 0002018150-25-000004 · form4-12162025_111219.xml · nonDerivative · entry 1 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,971 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document |
| October 12, 2025 Filed Oct 16, 2025 00:08 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 32,406 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0002018150-25-000003 · form4-10162025_121042.xml · derivative · entry 1 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,406 Underlying: Common Stock · 32,406 shares Expires 2035-10-12 F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:04 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 503,227 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000929638-24-001364 · form4.xml · derivative · entry 3 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,227 Underlying: Common Stock · 503,227 shares Expires 2033-10-31 F2 · price: On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement. F4 · price: Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:04 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 333,136 | Not disclosed Strike: $0.07 | Not disclosed |
DisclosureSEC source: 0000929638-24-001364 · form4.xml · derivative · entry 2 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,136 Underlying: Common Stock · 333,136 shares Expires 2033-10-31 F2 · price: On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement. F3 · price: Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:04 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 97,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000929638-24-001364 · form4.xml · nonDerivative · entry 1 Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.